keyword
MENU ▼
Read by QxMD icon Read
search

Triple negative breast cancer

keyword
https://www.readbyqxmd.com/read/29667444/akt2-sirna-delivery-with-amphiphilic-based-polymeric-micelles-show-efficacy-against-cancer-stem-cells
#1
Diana Rafael, Petra Gener, Fernanda Andrade, Joaquin Seras-Franzoso, Sara Montero, Yolanda Fernández, Manuel Hidalgo, Diego Arango, Joan Sayós, Helena F Florindo, Ibane Abasolo, Simó Schwartz, Mafalda Videira
Development of RNA interference-based therapies with appropriate therapeutic window remains a challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. A new amphihilic-based gene delivery system that combines Pluronic® F127 micelles with polyplexes spontaneously formed by electrostatic interaction between anionic siRNA and cationic polyethylenimine (PEI) 10K, was designed (PM)...
November 2018: Drug Delivery
https://www.readbyqxmd.com/read/29667115/biopsy-feasibility-trial-for-breast-cancer-pathologic-complete-response-detection-after-neoadjuvant-chemotherapy-imaging-assessment-and-correlation-endpoints
#2
Gaiane M Rauch, Henry M Kuerer, Beatriz Adrada, Lumarie Santiago, Tanya Moseley, Rosalind P Candelaria, Elsa Arribas, Jia Sun, Jessica W T Leung, Savitri Krishnamurthy, Wei T Yang
PURPOSE: This study was designed to present the secondary imaging endpoints of the trial for evaluating mammogram (MMG), ultrasound (US) and image guided biopsy (IGBx) assessment of pathologic complete response (pCR) in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC). METHODS: Patients with T1-3, N0-3, M0 triple-negative or HER2-positive BC who received NAC were enrolled in an Institutional Review Board-approved prospective, clinical trial...
April 17, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29666962/activity-of-indatuximab-ravtansine-against-triple-negative-breast-cancer-in-preclinical-tumor-models
#3
Kurt Schönfeld, Peter Herbener, Chantal Zuber, Thomas Häder, Katrin Bernöster, Christoph Uherek, Jörg Schüttrumpf
PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062) is an antibody-drug-conjugate that specifically targets CD138-expressing cells and has previously shown clinical activity in multiple myeloma. Here we show indatuximab ravtansine as a potential mono- and combination therapy for TNBC. METHODS: The effects of indatuximab ravtansine were assessed in vitro in SK-BR-3 and T47D breast cancer cell lines...
April 17, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29666469/a-p53-mir-30a-zeb2-axis-controls-triple-negative-breast-cancer-aggressiveness
#4
Alessandra di Gennaro, Valentina Damiano, Giulia Brisotto, Michela Armellin, Tiziana Perin, Antonella Zucchetto, Michela Guardascione, Herman P Spaink, Claudio Doglioni, B Ewa Snaar-Jagalska, Manuela Santarosa, Roberta Maestro
Inactivation of p53 contributes significantly to the dismal prognosis of breast tumors, most notably triple-negative breast cancers (TNBCs). How the relief from p53 tumor suppressive functions results in tumor cell aggressive behavior is only partially elucidated. In an attempt to shed light on the implication of microRNAs in this context, we discovered a new signaling axis involving p53, miR-30a and ZEB2. By an in silico approach we identified miR-30a as a putative p53 target and observed that in breast tumors reduced miR-30a expression correlated with p53 inactivation, lymph node positivity and poor prognosis...
April 17, 2018: Cell Death and Differentiation
https://www.readbyqxmd.com/read/29666142/tumor-xenograft-modeling-identifies-tcf4-itf2-loss-associated-with-breast-cancer-chemoresistance
#5
Gorka Ruiz de Garibay, Francesca Mateo, Agostina Stradella, Rafael Valdés-Mas, Luis Palomero, Jordi Serra-Musach, Diana A Puente, Ander Díaz-Navarro, Gardenia Vargas-Parra, Eva Tornero, Idoia Morilla, Lourdes Farré, María Martinez-Iniesta, Carmen Herranz, Emmet McCormack, August Vidal, Anna Petit, Teresa Soler, Conxi Lázaro, Xose S Puente, Alberto Villanueva, Miguel Angel Pujana
Understanding the mechanisms of cancer therapeutic resistance is fundamental to improving cancer care. There is clear benefit from chemotherapy in different breast cancer settings; however, knowledge of the mutations and genes that mediate resistance is incomplete. In this study, by modeling chemoresistance in patient-derived xenografts (PDXs), we show that adaptation to therapy is genetically complex and identify loss of transcription factor 4 (TCF4) associated with this process. A triple-negative BRCA1 -mutated PDX was used to study the genetics of chemoresistance...
April 13, 2018: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/29665100/accuracy-of-ultrasound-for-preoperative-assessment-of-tumor-size-in-patients-with-newly-diagnosed-breast-cancer-is-it-affected-by-the-background-parenchymal-echotexture
#6
Kyung Hee Ko, Eun Ju Son, In Wha Kim
OBJECTIVES: To assess the impact of the background parenchymal echotexture on the accuracy of tumor size estimation using breast ultrasound (US). METHODS: A total of 140 women with newly diagnosed invasive breast cancer from January 2014 to December 2015 were enrolled in this study. Two radiologists retrospectively reviewed US images in consensus for background parenchymal echotexture interpretation. The maximum tumor diameter from static images was recorded. Tumor size measurements were considered as having agreement with histologic results if they were within ±5 mm compared to the pathologic size...
April 17, 2018: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/29664846/a-comprehensive-program-enabling-effective-delivery-of-regional-genetic-counseling
#7
Jubilee Brown, Aly Athens, David L Tait, Erin K Crane, Robert V Higgins, R Wendel Naumann, Lejla Hadzikadic Gusic, Lisa Amacker-North
OBJECTIVES: The aim of this study was to demonstrate the utility of a comprehensive program involving management-based evidence, telemedicine, and patient navigation to provide genetic counseling services for patients with ovarian and breast cancer across a geographically large health care system. METHODS: We identified all patients with newly diagnosed ovarian and breast cancer in our health care system from January 2013 to December 2015 through the cancer registry...
April 16, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29663486/calmodulin-antagonist-enhances-dr5-mediated-apoptotic-signaling-in-tra-8-resistant-triple-negative-breast-cancer-cells
#8
Romone M Fancy, Harrison Kim, Tiara Napier, Donald J Buchsbaum, Kurt R Zinn, Yuhua Song
Patients with triple negative breast cancer (TNBC) have no successful "targeted" treatment modality, which represents a priority for novel therapy strategies. Upregulated death receptor 5 (DR5) expression levels in breast cancer cells compared to normal cells enable TRA-8, a DR5 specific agonistic antibody, to specifically target malignant cells for apoptosis without inducing normal hepatocyte apoptosis. Drug resistance is a common obstacle in TRAIL-based therapy for TNBC. Calmodulin (CaM) is overexpressed in breast cancer...
April 16, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29662198/the-mir-106b-25-cluster-mediates-breast-tumor-initiation-through-activation-of-notch1-via-direct-repression-of-nedd4l
#9
A L Guarnieri, C G Towers, D J Drasin, M U J Oliphant, Z Andrysik, T J Hotz, R L Vartuli, E S Linklater, A Pandey, S Khanal, J M Espinosa, H L Ford
Tumor-initiating cells (TIC) represent a subset of tumor cells with increased self-renewal capability. TICs display resistance to frontline cancer treatment and retain the ability to repopulate a tumor after therapy, leading to cancer relapse. NOTCH signaling has been identified as an important driver of the TIC population, yet mechanisms governing regulation of this pathway in cancer remain to be fully elucidated. Here we identify a novel mechanism of NOTCH regulation and TIC induction in breast cancer via the miR-106b-25 miRNA cluster...
April 17, 2018: Oncogene
https://www.readbyqxmd.com/read/29662002/carotenoid-lutein-selectively-inhibits-breast-cancer-cell-growth-and-potentiates-the-effect-of-chemotherapeutic-agents-through-ros-mediated-mechanisms
#10
Xiaoming Gong, Joshua R Smith, Haley M Swanson, Lewis P Rubin
Increasing evidence suggests that dietary carotenoids may reduce the risk of breast cancer. However, anti-breast cancer effects of carotenoids have been controversial, albeit understudied. Here, we investigated the effects of specific carotenoids on a wide range of breast cancer cell lines, and found that among several carotenoids (including β-carotene, lutein, and astaxanthin), lutein significantly inhibits breast cancer cell growth by inducing cell-cycle arrest and caspase-independent cell death, but it has little effect on the growth of primary mammary epithelial cells (PmECs)...
April 14, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29661738/overexpression-of-lox-in-triple-negative-breast-cancer
#11
Cornelia Leo, Christine Cotic, Victoria Pomp, Daniel Fink, Zsuzsanna Varga
BACKGROUND: Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is associated with a poor prognosis and typically earlier onset of metastasis in comparison with other breast cancer subtypes. Since TNBC lacks the expression of estrogen and progesterone receptors and Her2 status is also negative, there is currently no target that can be used for systemic therapy. Epithelial-mesenchymal transition (EMT) plays an important role in tumor progression and metastasis...
March 27, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29661243/effect-of-neoadjuvant-chemotherapy-regimen-on-relapse-free-survival-among-patients-with-breast-cancer-achieving-a-pathologic-complete-response-an-early-step-in-the-de-escalation-of-neoadjuvant-chemotherapy
#12
Anna Weiss, Sami I Bashour, Kenneth Hess, Alastair M Thompson, Nuhad K Ibrahim
BACKGROUND: Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize that once pCR has been achieved, there is no difference in subsequent postsurgical recurrence-free survival (RFS), whichever NACT regimen is used. METHODS: Data from patients with breast cancer who achieved pCR after NACT between 1996 and 2011 were reviewed. RFS was estimated by the Kaplan-Meier method, and differences between groups were assessed using log-rank testing...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29660596/time-trends-of-overall-survival-among-metastatic-breast-cancer-patients-in-the-real-life-esme-cohort
#13
Elisa Gobbini, Monia Ezzalfani, Véronique Dieras, Thomas Bachelot, Etienne Brain, Marc Debled, William Jacot, Marie Ange Mouret-Reynier, Anthony Goncalves, Florence Dalenc, Anne Patsouris, Jean Marc Ferrero, Christelle Levy, Veronique Lorgis, Laurence Vanlemmens, Claudia Lefeuvre-Plesse, Simone Mathoulin-Pelissier, Thierry Petit, Lionel Uwer, Christelle Jouannaud, Marianne Leheurteur, Magali Lacroix-Triki, Audrey Lardy Cleaud, Mathieu Robain, Coralie Courtinard, Christian Cailliot, David Perol, Suzette Delaloge
AIM: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort. METHODS: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014)...
April 13, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29659077/total-choline-quantification-measured-by-1h-mr-spectroscopy-as-early-predictor-of-response-after-neoadjuvant-treatment-for-locally-advanced-breast-cancer-the-impact-of-immunohistochemical-status
#14
Stylianos Drisis, Patrick Flamen, Michael Ignatiadis, Thierry Metens, Shih-Li Chao, Marie Chintinne, Marc Lemort
BACKGROUND: Validation of new biomarkers is essential for the early evaluation of neoadjuvant treatments. PURPOSE: To determine whether measurements of total choline (tCho) by 1H spectroscopy could predict morphological or pathological complete response (pCR) of neoadjuvant treatment and whether breast cancer subgroups are related to prediction accuracy. STUDY TYPE: Prospective, nonrandomized, monocentric, diagnostic study. POPULATION: Sixty patients were initially included with 39 women participating in the final cohort...
April 16, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29658592/in-vitro-cytotoxic-effect-of-parp-inhibitor-alone-and-in-combination-with-nab%C3%A2-paclitaxel-on-triple%C3%A2-negative-and-luminal-a-breast-cancer-cells
#15
Mehmet Topçul, İdi L Çeti N, Suna Özbaş Turan, Melek Özlem Kolusayin Ozar
In the present study, the in vitro cytotoxic effect of poly(ADP‑ribose) polymerase (PARP) inhibitor alone and in combination with nab‑paclitaxel was evaluated on human triple‑negative breast cancer (TNBC) cell line MDA‑MB‑231 and human luminal A breast cancer cell line MCF‑7. For this purpose, cell index (CI) values obtained from xCELLigence Real‑Time Cell Analysis (RTCA) DP instrument, mitotic index (MI), labelling index (LI) and apoptotic index (AI) analysis among cell kinetic parameters were used...
April 12, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29658179/vav1-down-modulates-akt-in-different-breast-cancer-subtypes-a-new-promising-chance-to-improve-breast-cancer-outcome
#16
Silvia Grassilli, Federica Brugnoli, Rossano Lattanzio, Marco Marchisio, Letizia Perracchio, Mauro Piantelli, Alberto Bavelloni, Silvano Capitani, Valeria Bertagnolo
Targeting different members of the Akt pathways is a promising therapeutic chance in solid tumors including breast cancer. The variable expression levels of Akt isoforms with opposite effects on tumor growth and metastasis, however, makes it difficult to select the inhibitors to be used for specific breast tumor subtypes. By using in vitro and in vivo models, we demonstrated here that Vav1, ectopically expressed in invasive breast tumors derived cells, down-modulates Akt acting at expression and/or activation levels depending on tumor subtype...
April 15, 2018: Molecular Oncology
https://www.readbyqxmd.com/read/29656345/update-on-the-treatment-of-early-stage-triple-negative-breast-cancer
#17
REVIEW
Priyanka Sharma
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is associated with poor long-term outcomes compared to other breast cancer subtypes. Currently, chemotherapy remains the main modality of treatment for early-stage TNBC, as there is no approved targeted therapy for this subtype. The biologic heterogeneity of TNBC has hindered the development and evaluation of novel agents, but recent advancements in subclassifying TNBC have paved the way for further investigation of more effective systemic therapies, including cytotoxic and targeted agents...
April 14, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29656222/prolactin-induced-protein-pip-is-a-potential-biomarker-for-early-stage-and-malignant-breast-cancer
#18
Anju Gangadharan, Themba Nyirenda, Kishan Patel, Nydia Jaimes-Delgadillo, Dominique Coletta, Takemi Tanaka, Ayal C Walland, Zena Jameel, Srinivasa Vedantam, Sittinon Tang, Ciaran Mannion, Grace Y Lee, Andre Goy, Andrew Pecora, K Stephen Suh
OBJECTIVES: Breast cancer (BC) is the second leading cause of cancer-related mortality in women. Bioinformatic analysis and expression screening showed that Prolactin Induced Protein (PIP) was differentially expressed in BC. The objective of this investigation was to characterize the expression pattern of PIP, an aspartyl proteinase, in malignant and non-malignant breast tissues. MATERIALS AND METHODS: Real time quantitative PCR was employed to analyze PIP and androgen receptor (AR) mRNA levels in BC cell lines and 190 normal tissues and tumor samples...
April 12, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29652946/-impact-of-the-chilean-explicit-guaranties-health-system-ges-on-breast-cancer-treatment
#19
César Del Castillo Sm, M Elena Cabrera C, Lea Derio P, Fancy Gaete V, Gabriel Cavada Ch
Background Breast cancer is the most common malignant tumor in women in the world. In 2005, it was incorporated to the Explicit Guaranties Health System (GES) in Chile. Aim To describe the demographic and clinical characteristics of breast cancer patients and to determine the effect of incorporating these women to GES. Material and Methods Medical records of 5,119 women with breast cancer aged 59 ± 14 years, attended at six public hospitals between 2000 and 2010 were reviewed. Median follow up was 87 months (range 1-182)...
December 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29652200/bursera-copallifera-extracts-have-cytotoxic-and-migration-inhibitory-effects-in-breast-cancer-cell-lines
#20
Fabiola Domínguez, Paola Maycotte, Adilene Acosta-Casique, Sofía Rodríguez-Rodríguez, Diego A Moreno, Federico Ferreres, Juan Carlos Flores-Alonso, María Guadalupe Delgado-López, Martín Pérez-Santos, Maricruz Anaya-Ruiz
Plants from the Bursera genus are widely distributed in the tropical dry forests of Mexico. In traditional medicine, extracts from different species of Bursera have been used for a wide range of biological activities, including the treatment of cancer-related symptoms. Compounds present in the Bursera genus include lignans, flavonoids, steroids, short-chain aliphatic alkanes, acetates, alcohols, ketones, and terpenoids. In some instances, secondary metabolites of these classes of compounds may induce cytotoxicity, and therefore we sought to investigate the effects of B...
April 1, 2018: Integrative Cancer Therapies
keyword
keyword
3592
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"